Details

Ruben Vrolijk, MSc

Position
Scientific Employee
Program
Drug Monitoring & Policy
Telephone
+31 (0)30 - 2959(461)
E-mail
Contact page
Online
Ruben  Vrolijk

Expertise

Ruben Vrolijk is a Scientific Employee at the Drug Monitoring and Information System (DIMS). DIMS is a monitoring tool for the Dutch drug market, operational since 1992. The system revolves around the analysis of user supplied drugs, and focusses on both monitoring the drug markets and supplying users with harm-reduction information. Ruben Vrolijk has a background in toxicology, and focusses primarily on the development of new analytical techniques for drug analysis, like Fourier Transform Infrared Spectroscopy,  and the overall management and functioning of the DIMS.   

Inspiration and mission

Though my work at DIMS, my main activities revolve around the analysis of data on drugs. The opportunity to do this on the scale of DIMS, with over 10.000 samples per year, is unique. It has resulted in a dataset which structurally leads to new insights on drugs and drug markets, both nationally and internationally. One of the biggest challenges in drug related research is the illegal character of the substances of interest; while the adverse effects of most medicinal substances are often well documented, the adverse effects illegal drugs are less well known and communicated, while their user-population can be significantly larger. This contradiction inspires me to do the work that I do: monitor the drug market, but also communicate and warn where necessary, and form a dataset on which future research on drugs can build. 

Currently working on…

At the moment, I primarily focus on the development and implementation of new, complimentary, analytical methods for the DIMS. The supply of drug samples to the DIMS is greater than the (financial) capacity via conventional testing methods (GC-MS/LC-DAD). Though the development of new and cheaper techniques, we hope to able get an even more complete picture of the Dutch drugs Market, and supply more users with harm-reduction information.

Relevant links

Linkedin

ResearchGate

Vrolijk, R.Q., Brunt, T.M., Vreeker, A., & Niesink, R.J.M. (2017). Is online information on ecstasy tablet content safe? Addiction, 112(1), 94-100. doi:10.1111/add.13559